The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy
Open accessAbstract
Lenvatinib, a multi-target tyrosine kinase inhibitor (TKI), is an emerging first-line therapy for hepatocellular carcinoma (HCC). Its application has changed the status of sorafenib as the only first-line TKI treatment for HCC for more than a decade. Evidence has shown that lenvatinib possesses antitumor proliferation and immunomodulatory activity in preclinical studies. In comparison, lenvatinib was non-inferior to sorafenib in overall survival (OS), and even shows superiority with regard to all the secondary efficacy endpoints. Immune-checkpoint inhibitors(ICIs)are now being incorporated into HCC treatment. Positive outcomes have been achieved in the combination of lenvatinib plus ICIs, bringing broader prospects for HCC. This review presents an overview on the therapeutic mechanisms and clinical efficacy of lenvatinib in HCC, and we discuss the future perspectives of lenvatinib in HCC management with focus on biomarker-guided precision medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
El–Serag, H. B., & Rudolph, K. L. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.061 · Cited by 5,415
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y.-H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32453-9 · Cited by 3,653
Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and Angiogenesis
Hicklin, D. J., & Ellis, L. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.081 · Cited by 3,007
Fibroblast growth factor signalling: from development to cancer
Turner, N., & Grose, R. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2780 · Cited by 2,693
Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30351-6 · Cited by 2,479
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Abou-Alfa, G. K., Meyer, T., Cheng, A.-L., El-Khoueiry, A. B., Rimassa, L., Ryoo, B.-Y., Cicin, I., Merle, P., Chen, Y., Park, J.-W., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1717002 · Cited by 2,344
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Schlumberger, M., Tahara, M., Wirth, L. J., Robinson, B., Brose, M. S., Elisei, R., Habra, M. A., Newbold, K., Shah, M. H., Hoff, A. O., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406470 · Cited by 2,096
Cellular signaling by fibroblast growth factor receptors
Eswarakumar, V. P., Lax, I., & Schlessinger, J. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.001 · Cited by 1,929
Zhu, A. X., Kang, Y.-K., Yen, C.-J., Finn, R. S., Galle, P. R., Llovet, J. M., Assenat, E., Brandi, G., Pracht, M., Lim, H. Y., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30937-9 · Cited by 1,662
Signal transduction by vascular endothelial growth factor receptors
Koch, S., Tugues, S., Li, X., Gualandi, L., & Claesson-Welsh, L. (2011) · Biochemical Journal · doi:10.1042/bj20110301 · Cited by 1,635
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Voron, T., Colussi, O., Marcheteau, E., Pernot, S., Nizard, M., Pointet, A.-L., Latreche, S., Bergaya, S., Benhamouda, N., Tanchot, C., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20140559 · Cited by 1,179
Gabrilovich, D., Ishida, T., Oyama, T., Ran, S., Kravtsov, V., Nadaf, S., & Carbone, D. P. (1998) · Blood · doi:10.1182/blood.v92.11.4150 · Cited by 1,048
Takahashi, H., & Shibuya, M. (2005) · Clinical Science · doi:10.1042/cs20040370 · Cited by 953
Cheng, A.-L., Kang, Y.-K., Lin, D.-Y., Park, J.-W., Kudo, M., Qin, S., Chung, H.-C., Song, X., Xu, J., Poggi, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.8372 · Cited by 777
Johnson, P. J., Qin, S., Park, J.-W., Poon, R. T. P., Raoul, J.-L., Philip, P. A., Hsu, C.-H., Hu, T.-H., Heo, J., Xu, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4410 · Cited by 772
Wallin, J. J., Bendell, J. C., Funke, R., Sznol, M., Korski, K., Jones, S., Hernandez, G., Mier, J., He, X., Hodi, F. S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12624 · Cited by 713
Cainap, C., Qin, S., Huang, W.-T., Chung, I. J., Pan, H., Cheng, Y., Kudo, M., Kang, Y.-K., Chen, P.-J., Toh, H.-C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.3298 · Cited by 629
Matsui, J., Yamamoto, Y., Funahashi, Y., Tsuruoka, A., Watanabe, T., Wakabayashi, T., Uenaka, T., & Asada, M. (2008) · International Journal of Cancer · doi:10.1002/ijc.23131 · Cited by 551
Matsui, J., Funahashi, Y., Uenaka, T., Watanabe, T., Tsuruoka, A., & Asada, M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5270 · Cited by 530
Yamamoto, Y., Matsui, J., Matsushima, T., Obaishi, H., Miyazaki, K., Nakamura, K., Tohyama, O., Semba, T., Yamaguchi, A., Hoshi, S., et al. (2014) · Vascular Cell · doi:10.1186/2045-824x-6-18 · Cited by 507
Siegel, A. B., Cohen, E. I., Ocean, A., Lehrer, D., Goldenberg, A., Knox, J. J., Chen, H., Clark-Garvey, S., Weinberg, A., Mandeli, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9947 · Cited by 506
Tohyama, O., Matsui, J., Kodama, K., Hata-Sugi, N., Kimura, T., Okamoto, K., Minoshima, Y., Iwata, M., & Funahashi, Y. (2014) · Journal of Thyroid Research · doi:10.1155/2014/638747 · Cited by 475
RET tyrosine kinase signaling in development and cancer
Arighi, E., Borrello, M. G., & Sariola, H. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.05.010 · Cited by 468
Kato, Y., Tabata, K., Kimura, T., Yachie-Kinoshita, A., Ozawa, Y., Yamada, K., Ito, J., Tachino, S., Hori, Y., Matsuki, M., et al. (2019) · PLOS ONE · doi:10.1371/journal.pone.0212513 · Cited by 460
Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
Llovet, J. M., & Hernandez-Gea, V. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0547 · Cited by 397
A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma
Romei, C., Ciampi, R., & Elisei, R. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.11 · Cited by 352
Finn, R. S., Merle, P., Granito, A., Huang, Y.-H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Gerolami, R., Caparello, C., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.04.010 · Cited by 347
Eskens, F. A. L. M., & Verweij, J. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.09.015 · Cited by 342
Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
Ikeda, K., Kudo, M., Kawazoe, S., Osaki, Y., Ikeda, M., Okusaka, T., Tamai, T., Suzuki, T., Hisai, T., Hayato, S., et al. (2017) · Journal of Gastroenterology · doi:10.1007/s00535-016-1263-4 · Cited by 338
Kimura, T., Kato, Y., Ozawa, Y., Kodama, K., Ito, J., Ichikawa, K., Yamada, K., Hori, Y., Tabata, K., Takase, K., et al. (2018) · Cancer Science · doi:10.1111/cas.13806 · Cited by 336
Hepatocellular carcinoma (HCC): beyond sorafenib—chemotherapy
Kim, D. W., Talati, C., & Kim, R. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.09.07 · Cited by 333
Control of the Immune Response by Pro-Angiogenic Factors
Voron, T., Marcheteau, E., Pernot, S., Colussi, O., Tartour, E., Taieb, J., & Terme, M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00070 · Cited by 325
Okamoto, K., Kodama, K., Takase, K., Sugi, N. H., Yamamoto, Y., Iwata, M., & Tsuruoka, A. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.07.007 · Cited by 288
Regulation of growth factor signaling by FRS2 family docking/scaffold adaptor proteins
Gotoh, N. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00840.x · Cited by 268
Matsuki, M., Hoshi, T., Yamamoto, Y., Ikemori‐Kawada, M., Minoshima, Y., Funahashi, Y., & Matsui, J. (2018) · Cancer Medicine · doi:10.1002/cam4.1517 · Cited by 266
Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth
Hansen, W., Hutzler, M., Abel, S., Alter, C., Stockmann, C., Kliche, S., Albert, J., Sparwasser, T., Sakaguchi, S., Westendorf, A. M., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111497 · Cited by 250
Xiang, Q., Chen, W., Ren, M., Wang, J., Zhang, H., Deng, D. Y. B., Zhang, L., Shang, C., & Chen, Y. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2620 · Cited by 229
Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib
Reig, M., Torres, F., Rodriguez-Lope, C., Forner, A., LLarch, N., Rimola, J., Darnell, A., Ríos, J., Ayuso, C., & Bruix, J. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.03.030 · Cited by 228
Huynh, H., Ngo, V. C., Fargnoli, J., Ayers, M., Soo, K. C., Koong, H. N., Thng, C. H., Ong, H. S., Chung, A., Chow, P., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0509 · Cited by 221
Xue, R., Li, R., Guo, H., Guo, L., Su, Z., Ni, X., Qi, L., Zhang, T., Li, Q., Zhang, Z., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.12.033 · Cited by 214
Angiopoietin-2: An Attractive Target for Improved Antiangiogenic Tumor Therapy
Gerald, D., Chintharlapalli, S., Augustin, H. G., & Benjamin, L. E. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4697 · Cited by 202
Al-Abd, A. M., Alamoudi, A. J., Abdel-Naim, A. B., Neamatallah, T. A., & Ashour, O. M. (2017) · Journal of Advanced Research · doi:10.1016/j.jare.2017.06.006 · Cited by 198
Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
Ikeda, M., Okusaka, T., Mitsunaga, S., Ueno, H., Tamai, T., Suzuki, T., Hayato, S., Kadowaki, T., Okita, K., & Kumada, H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1354 · Cited by 186
FGF19–FGFR4 Signaling in Hepatocellular Carcinoma
Raja, A., Park, I., Haq, F. U., & Ahn, S. (2019) · Cells · doi:10.3390/cells8060536 · Cited by 173
Review article: systemic treatment of hepatocellular carcinoma
Pinter, M., & Peck‐Radosavljevic, M. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14913 · Cited by 160
Heo, J., Breitbach, C. J., Moon, A., Kim, C. W., Patt, R., Kim, M. K., Lee, Y. K., Oh, S. Y., Woo, H. Y., Parato, K. A., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.39 · Cited by 156
Huang, H., Lai, J.-Y., Do, J., Liu, D., Li, L., Rosario, J. D., Doppalapudi, V. R., Pirie-Shepherd, S. R., Levin, N., Bradshaw, C. W., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2317 · Cited by 142
Nixon, A. B., Pang, H., Starr, M. D., Friedman, P. N., Bertagnolli, M. M., Kindler, H. L., Goldberg, R. M., Venook, A. P., & Hurwitz, H. I. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0926 · Cited by 104
Tamai, T., Hayato, S., Hojo, S., Suzuki, T., Okusaka, T., Ikeda, K., & Kumada, H. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.917 · Cited by 103
STAT3 Mediates Regorafenib-Induced Apoptosis in Hepatocellular Carcinoma
Tai, W., Chu, P., Shiau, C., Chen, Y., Li, Y.-S., Hung, M., Chen, L., Chen, P., Su, J., Lin, P., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0725 · Cited by 101
Self-citationPeng, S., Wang, Y., Peng, H., Chen, D., Shen, S., Peng, B., Chen, M., Lencioni, R. A., & Kuang, M. (2014) · Hepatology · doi:10.1002/hep.27236 · Cited by 99
Immunological Effects of Bevacizumab-Based Treatment in Metastatic Colorectal Cancer
Manzoni, M., Rovati, B., Ronzoni, M., Loupakis, F., Mariucci, S., Ricci, V., Gattoni, E., Salvatore, L., Tinelli, C., Villa, E., et al. (2010) · Oncology · doi:10.1159/000320609 · Cited by 97
Understanding the Genetic Mechanisms of Cancer Drug Resistance Using Genomic Approaches
Hu, X., & Zhang, Z. (2015) · Trends in Genetics · doi:10.1016/j.tig.2015.11.003 · Cited by 95
Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients
Martino, E., Misso, G., Pastina, P., Costantini, S., Vanni, F., Gandolfo, C., Botta, C., Capone, F., Lombardi, A., Pirtoli, L., et al. (2016) · Cell Death Discovery · doi:10.1038/cddiscovery.2016.25 · Cited by 94
Fibroblast growth factor signaling in liver carcinogenesis
Sandhu, D. S., Baichoo, E., & Roberts, L. R. (2013) · Hepatology · doi:10.1002/hep.26679 · Cited by 87
Hoshi, T., Miyano, S. W., Watanabe, H., Sonobe, R. M. K., Seki, Y., Ohta, E., Nomoto, K., Matsui, J., & Funahashi, Y. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.02.015 · Cited by 84
Tahara, M., Schlumberger, M. J., Elisei, R., Habra, M. A., Kiyota, N., Paschke, R., Dutcus, C. E., Hihara, T., McGrath, S. M., Matijevic, M., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.013 · Cited by 82
Lin, Y., Tan, C., Chen, C.-W., Ou, D., Cheng, A., & Hsu, C. (2018) · Seminars in Liver Disease · doi:10.1055/s-0038-1673621 · Cited by 82
Ogasawara, S., Yano, H., Iemura, A., et al. (1996) · Hepatology · doi:10.1002/hep.510240132 · Cited by 81
Ma, X., Qiu, Y., Sun, Y., Zhu, L., Zhao, Y., Li, T., Lin, Y., Ma, D., Qin, Z., Sun, C., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2368-5 · Cited by 81
Self-citationPishvaian, M. J., Lee, M. S., Ryoo, B., Stein, S., Lee, K. H., Verret, W. J., Spahn, J. H., Shao, H., Liu, B., Iizuka, K., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy424.028 · Cited by 76
Tseng, P., Tai, M., Huang, C., Wang, C., Lin, J., Hung, C., Chen, C., Wang, J., Lu, S., Lee, C., et al. (2008) · Journal of Surgical Oncology · doi:10.1002/jso.21109 · Cited by 72
Matsuki, M., Adachi, Y., Ozawa, Y., Kimura, T., Hoshi, T., Okamoto, K., Tohyama, O., Mitsuhashi, K. O., Yamaguchi, A., Matsui, J., et al. (2017) · Cancer Science · doi:10.1111/cas.13169 · Cited by 68
Zheng, A., Chevalier, N., Calderoni, M., Dubuis, G., Dormond, O., Ziros, P. G., Sykiotis, G. P., & Widmann, C. (2019) · Oncotarget · doi:10.18632/oncotarget.27361 · Cited by 68
Zhu, A. X., Finn, R. S., Ikeda, M., Sung, M. W., Baron, A. D., Kudo, M., Okusaka, T., Kobayashi, M., Kumada, H., Kaneko, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.4519 · Cited by 68
Ramucirumab: A Review in Hepatocellular Carcinoma
Syed, Y. Y. (2020) · Drugs · doi:10.1007/s40265-020-01263-6 · Cited by 62
Chuma, M., Uojima, H., Numata, K., Hidaka, H., Toyoda, H., Hiraoka, A., Tada, T., Hirose, S., Atsukawa, M., Itokawa, N., et al. (2020) · Cancers · doi:10.3390/cancers12020293 · Cited by 58
Antiproliferative Effect of Lenvatinib on Human Liver Cancer Cell Lines In Vitro and In Vivo
Ogasawara, S., Mihara, Y., Kondo, R., Kusano, H., Akiba, J., & Yano, H. (2019) · Anticancer Research · doi:10.21873/anticanres.13802 · Cited by 57
Personalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker Selection
Zhang, B., & Finn, R. S. (2016) · Liver Cancer · doi:10.1159/000367763 · Cited by 49
Sueta, D., Suyama, K., Sueta, A., Tabata, N., Yamashita, T., Tomiguchi, M., Takeshita, T., Yamamoto‐Ibusuki, M., Yamamoto, E., Izumiya, Y., et al. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.03.039 · Cited by 49
Kato, Y., Bao, X., Macgrath, S., Tabata, K., Hori, Y., Tachino, S., Matijevici, M., Funahashi, Y., & Matsui, J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw362.02 · Cited by 45
Kuzuya, T., Ishigami, M., Ito, T., et al. (2020) · Anticancer Research · doi:10.21873/anticanres.14167 · Cited by 44
Zhang, Q., Liu, H., Wang, H., Lü, M., Miao, Y., Ding, J., Li, H., Gao, X., Sun, S., & Zheng, J. (2019) · PubMed · Cited by 44
Genetic Biomarkers For Hepatocellular Carcinoma In The Era Of Precision Medicine
Duan, J., Wu, Y., Liu, J., Zhang, J., Fu, Z., Feng, T., Liu, M., Han, J., Li, Z., & Chen, S. (2019) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s224849 · Cited by 42
Unique Metabolic Pathway of [14C]Lenvatinib after Oral Administration to Male Cynomolgus Monkey
Inoue, K., Asai, N., Mizuo, H., Fukuda, K., Kusano, K., & Yoshimura, T. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.043281 · Cited by 35
Corosolic acid reduces 5‑FU chemoresistance in human gastric cancer cells by activating AMPK
Park, J. T., Lee, J., Lee, M., Cha, E., Kim, S., & Sul, J. Y. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9244 · Cited by 33
Finn, R. S., Kudo, M., Cheng, A., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy269.057 · Cited by 27
Assessment of lenvatinib treatment for unresectable hepatocellular carcinoma with liver cirrhosis
Komatsu, S., Yano, Y., Sofue, K., Kido, M., Tanaka, M., Kuramitsu, K., Awazu, M., Gon, H., Yamamoto, A., Yanagimoto, H., et al. (2020) · HPB · doi:10.1016/j.hpb.2020.03.002 · Cited by 14
Treatment of Hepatocellular Carcinoma With Lenvatinib.
Han, K. (2018) · Europe PMC (PubMed Central) · Cited by 7
Multimodal and sequential treatment improves survival in patients with hepatocellular carcinoma
Göbel, T., Graf, D., Hosnowsky, C., Blondin, D., Knoefel, W. T., Häussinger, D., & Erhardt, A. (2016) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0042-121264 · Cited by 5
Ichikawa, K., Miyano, S. W., Adachi, Y., Yamamoto, Y., Ozawa, Y., Funahashi, Y., Okamoto, K., Nomoto, K., & Matsui, J. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-1374 · Cited by 5
Cited by
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Self-citationHepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers
Wang, Y., & Deng, B. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10084-4 · Cited by 415
Loh, J.-J., & Ma, S. (2024) · Cell Stem Cell · doi:10.1016/j.stem.2024.04.004 · Cited by 314
Chen, Q., Chen, Z., Li, F., Zha, H., He, W., Jiang, F., Wei, J., Xu, J., Li, R., Cai, L., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115456 · Cited by 14
Metadata
- Authors
- Zhao, Y., Zhang, Y.-N., Wang, K.-T., & Chen, L.
- Venue
- Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
- Publisher
- Elsevier BV
- Published
- 2020-08
- Volume
- 1874
- Issue
- 1
- Pages
- 188391
- ISSN
- 0304-419X (ISSN-L)
- OpenAlex
- W3042066166
- Cited by
- 278
- References
- 89
- FWCI
- 14.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.